A
Alexza Pharmaceuticals
Alexza Pharmaceuticals - Alexza Pharmaceuticals - Welcome
About Alexza Pharmaceuticals
Founded in 2000 by Alejandro Zaffaroni and Thomas B. King, Alexza Pharmaceuticals embarked on a mission to innovate drug delivery systems. The company focused on developing proprietary products for acute and intermittent conditions, utilizing their unique Staccato system. This technology allowed for rapid drug delivery through inhalation, offering a novel approach to treatment.
In March 2006, Alexza Pharmaceuticals made a significant leap by going public. The company staged its Initial Public Offering (IPO), pricing 5.5 million shares at $8 each. This move was pivotal, providing the necessary capital to advance their research and development efforts.
A decade later, in May 2016, Alexza Pharmaceuticals experienced another major milestone. The company was acquired by Grupo Ferrer Internacional for $55 million. This acquisition marked a new chapter, integrating Alexza's innovative technologies with Ferrer's global reach and resources.
Throughout its journey, Alexza Pharmaceuticals remained committed to transforming patient care through its cutting-edge inhalation therapies. The company's story is a testament to the impact of innovation in the pharmaceutical industry, highlighting the potential of novel drug delivery systems to improve treatment outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Mountain View, United States
- Listing
- IPO 2006
- Employees
- 84
- Open positions
- 5
- Dealroom signal
- 60.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2016 | $5M | — | Undisclosed | — |
| POST IPO EQUITYOther financing | Mar 2014 | $45M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $5M | 0% |
| 2025 | $5M | 0% |
| 2024 | $5M | 0% |
| 2023 | $5M | 0% |
| 2022 | $5M | 0% |
| 2021 | $5M | 0% |
| 2020 | $5M | — |
Growth signals
Latest recorded traffic for Alexza Pharmaceuticals is 2.6K monthly website visits, up 100% over the last three months. Alexza Pharmaceuticals's team declined 25% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alexza Pharmaceuticals in the Mountain View ecosystem
The Alexza Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Versant Ventures
Frazier Healthcare Partners
NEA
Series B and later5 investors entered at this stage
- AVAlloy Ventures
Delphi Ventures
5AM Ventures- MCMDS Capital
- PVPacific Rim Ventures
Other known investors4 additional known investors
Stanford University
Abingworth
Hercules Capital
Lumira Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alexza Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alexza Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









